Therapeutic potential of replication-selective oncolytic adenoviruses on cells from familial and sporadic desmoid tumors

Clinical Cancer Research

Volumn 14, Issue 19, 2008, Pages 6187-6192

  Peerlinck, Inge ^a   Amini Nik, Saeid ^b   Phillips, Robin K ^c   Iggo, Richard ^d   Lemoine, Nicholas R ^a   Tejpar, Sabine ^b   Vassaux, Georges ^e,f  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Laboratorium Voor Moleculaire Diagnostiek   (Belgium)

^c ST MARK S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF ST ANDREWS   (United Kingdom)

^e HÔTEL DIEU   (France)

^f UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC ADENOVIRUS; WNT PROTEIN; ONCOLYTIC VIRUS;

ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DESMOID TUMOR; DRUG SENSITIVITY; FAMILIAL CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSGENE; VIRUS INFECTIVITY; VIRUS REPLICATION; ADENOVIRUS; CELL SEPARATION; ENTEROVIRUS; FIBROMATOSIS; FLOW CYTOMETRY; GENETICS; METABOLISM; METHODOLOGY; NEOPLASM; ONCOLYTIC VIROTHERAPY; PHYSIOLOGY; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE;

ADENOVIRIDAE; CELL LINE, TUMOR; CELL SEPARATION; ENTEROVIRUS; FIBROMATOSIS, AGGRESSIVE; FLOW CYTOMETRY; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TRANSGENES; VIRUS REPLICATION;

EID: 58149163337     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0410     Document Type: Article

References (48)

1. Sturt NJ, Clark SK. Current ideas in desmoid tumours. Fam Cancer 2006;5:275-85.
2. Sakorafas GH, Nissotakis C, Peros G. Abdominal desmoid tumors. Surg Oncol 2007;16:131-42.
3. Tejpar S, Michils G, Denys H, et al. Analysis of Wnt/β catenin signalling in desmoid tumors. Acta Gastroenterol Belg 2005;68:5-9.
4. Signoroni S, Frattini M, Negri T, et al. Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin Cancer Res 2007;13:5034-40.
5. Sturt NJ, Gallagher MC, Bassett P, et al. Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline APC mutation. Gut 2004;53:1832-6.
6. Wunder JS, Nielsen TO, Maki RG, O'Sullivan B, Alman BA. Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol 2007;8:513-24.
7. Kotiligam D, Lazar AJ, Pollock RE, Lev D. Desmoid tumor: a disease opportune for molecular insights. Histol Histopathol 2008;23:117-26.
8. Tolan S, Shanks JH, Loh MY, Taylor B, Wylie JP. Fibromatosis: benign by name but not necessarily by nature. Clin Oncol R Coll Radiol 2007;19:319-26.
9. Latchford AR, Sturt NJ, Neale K, Rogers PA, Phillips RK. A 10-year review of surgery for desmoid disease associated with familial adenomatous polyposis. Br J Surg 2006;93:1258-64.
10. Bright-Thomas RM, Agrawal A, Hargest R. Preclinical studies of gene transfer for the treatment of desmoid disease in familial adenomatous polyposis. Br J Surg 2002;89:1563-9.
11. Martinico SC, Jezzard S, Sturt NJ, et al. Assessment of endostatin gene therapy for familial adenomatous polyposis-related desmoid tumors. Cancer Res 2006;66:8233-40.
12. Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: from basic science to clinical application. J Pathol 2006;208:299-318.
13. Alemany R. Cancer selective adenoviruses. Mol Aspects Med 2007;28:42-58.
14. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-6.
15. Gomez-Manzano C, Alonso MM, Yung WK, et al. Δ-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res 2006;12:556-62.
16. Cascallo M, Gros A, Bayo N, Serrano T, Capella G, Alemany R. Deletion of VAI, VAII RNA. Genes in the design of oncolytic adenoviruses. Hum Gene Ther 2006;17:929-40.
17. Fuerer C, Iggo R. Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of thewnt signalling pathway. Gene Ther 2002;9:270-81.
18. Merron A, Peerlinck I, Martin-Duque P, et al. SPECT/CTi maging of oncolytic adenovirus propagation in tumours in vivo using the Na/I symporter as a reporter gene. Gene Ther 2007;14:1731-8.
19. Bilsland AE, Merron A, Vassaux G, Keith WN. Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses. Cancer Res 2007;67:1299-307.
20. Hermiston T. A demand for next-generation oncolytic adenoviruses. Curr Opin Mol Ther 2006;8:322-30.
21. Homicsko K, Lukashev A, Iggo RD. RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer. Cancer Res 2005;65:6882-90.
22. Groot-Wassink T, Aboagye EO, Wang Y, Lemoine NR, Keith WN, Vassaux G. Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice. Cancer Res 2004;64:4906-11.
23. Groot-Wassink T, Aboagye EO, Wang Y, Lemoine NR, Reader AJ, Vassaux G. Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal. Mol Ther 2004;9:436-42.
24. Vassaux G, Hurst HC, Lemoine NR. Insulation of a conditionally expressed transgene in an adenoviral vector. Gene Ther 1999;6:1192-97.
25. Groot-Wassink T, Aboagye EO, Glaser M, Lemoine NR, Vassaux G. Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther 2002;13:1723-35.
26. Gagnebin J, Brunori M, Otter M, Juillerat-Jeanneret L, Monnier P, Iggo R. A photosensitising adenovirus for photodynamic therapy. Gene Ther 1999;6:1742-50.
27. Martin-Duque P, Jezzard S, Kaftansis L, Vassaux G. Direct comparison of the insulating properties of two genetic elements in an adenoviral vector containing two different expression cassettes. Hum Gene Ther 2004;15:995-1002.
28. Critchley RJ, Jezzard S, Radford KJ, et al. Potential therapeutic applications of recombinant, invasive E. coli. Gene Ther 2004;11:1224-33.
29. Critchley-Thorne RJ, Stagg AJ, Vassaux G. Recombinant Escherichia coli expressing invasin targets the Peyer's patches: the basis for a bacterial formulation for oral vaccination. Mol Ther 2006;14:183-91.
30. Wang Y, Thorne S, Hannock J, et al. A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses. Clin Cancer Res 2005;11:351-60.
31. Morin PJ, Sparks AB, Korinek V, et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 1997;275:1787-90.
32. Bergelson JM. Receptors mediating adenovirus attachment and internalization. Biochem Pharmacol 1999;57:975-9.
33. Vincent T, Pettersson RF, Crystal RG, Leopold PL. Cytokine-mediated down-regulation of coxsackievirus-adenovirus receptor in endothelial cells. J Virol 2004;78:8047-58.
34. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879-85.
35. Alonso MM, Gomez-Manzano C, Jiang H, et al. Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. Cancer Gene Ther 2007;14:756-61.
36. Cheong SC, Wang Y, Meng JH, et al. E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models. Cancer Gene Ther 2008;15:40-50.
37. Gu W, Ogose A, Kawashima H, et al. High-level expression of the coxsackievirus and adenovirus receptor messenger RNA in osteosarcoma, Ewing's sarcoma, and benign neurogenic tumors among musculoskeletal tumors. Clin Cancer Res 2004;10:3831-8.
38. Nicklin SA, Wu E, Nemerow GR, Baker AH. The influence of adenovirus fiber structure and function on vector development for gene therapy. Mol Ther 2005;12:384-93.
39. Dechecchi MC, Melotti P, Bonizzato A, Santacatterina M, Chilosi M, Cabrini G. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 2001;75:8772-80.
40. Waddington SN, Parker AL, Havenga M, et al. Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. J Virol 2007;81:9568-71.
41. Waddington SN, McVey JH, Bhella D, et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008;132:397-409.
42. Favre D, Cherel Y, Provost N, et al. Hyaluronidase enhances recombinant adeno-associated virus (rAAV)-mediated gene transfer in the rat skeletal muscle. Gene Ther 2000;7:1417-20.
43. Boelaert K, Franklyn JA. Sodium iodide symporter: a novel strategy to target breast, prostate, and other cancers? Lancet 2003;361:796-7.
44. Groot-Wassink T, Barthel H, Lemoine NR, Vassaux G. Sodium iodide symporter: a new strategy to target cancer? Lancet 2003;361:1905-6.
45. Boland A, Ricard M, Opolon P, et al. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 2000;60:3484-92.
46. Cho JY, Shen DH, Yang W, et al. In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas. Gene Ther 2002;9:1139-45.
47. Spitzweg C, Baker CH, Bergert ER, O'Connor MK, Morris JC. Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression. Hum Gene Ther 2007;18:916-24.
48. Zhang L, Sharma S, Zhu LX, et al. Nonradioactive iodide effectively induces apoptosis in genetically modified lung cancer cells. Cancer Res 2003;63:5065-72.